Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07265596 · ClinicalTrials.gov registry record · Phase 2
Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
A Phase 2 study of Prodromal Parkinsons Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT07265596: Recruiting Phase 2 study of Prodromal Parkinsons Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
NCT07265596 is a Phase 2 study of Prodromal Parkinsons Disease that is actively recruiting participants, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07265596, a Phase 2 study of Prodromal Parkinsons Disease, is actively recruiting participants, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months. Approximately 100 Prodromal participants will be recruited from up to 10 sites. Participants will be comprehensively assessed at baseline and follow up. Participants will undergo imaging assessments with \[18F\] AV-133 and clinical (motor, neuropsychiatric, cognitive and imaging and biomarker) assessments (conducted under the PPMI Clinical protocol).
Primary Outcome
The mean rates of change and the variability around the mean of \[18F\]AV-133 PET SUVr in Prodromal PD patients, and where appropriate the comparison of these rates between patient subsets at study intervals ranging from 12 months to 24 months.
Conditions Studied
Interventions
- DRUG [18F] AV-133 PET Imaging
Study Locations (8)
Other
- Philipps-University of Marburg - Hessen
- Tel Aviv Sourasky Medical Center - Tel Aviv
Connecticut
- Institute for Neurodegenerative Disorders - New Haven
Pennsylvania
- University of Pennsylvania - Philadelphia
Ontario
- Toronto Western Hospital - Toronto
Gelderland
- Radboud University - Nijmegen
Britain
- Queen Mary University of London - London
Tyne and Wear
- Newcastle University - Newcastle upon Tyne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT07265596 shows while recruiting
NCT07265596 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Prodromal Parkinsons Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F] AV-133 PET Imaging is the first listed.
NCT07265596 lists 8 locations in 7 states (Other, Connecticut, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT07265596 about?
NCT07265596 is a clinical study titled "Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)". The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months. Approximately 100 Prodromal participants will be recruited from up to 10 sites. Participants will be comprehensively assess...
What is the current status of trial NCT07265596?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-10-30. Estimated completion is 2027-12.
What conditions does trial NCT07265596 study?
This clinical trial studies the following conditions: Prodromal Parkinsons Disease.
What interventions are being tested in trial NCT07265596?
The interventions under investigation include: [18F] AV-133 PET Imaging (DRUG).
Who is sponsoring clinical trial NCT07265596?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07265596 being conducted?
This trial has 8 study locations across Connecticut, Pennsylvania, Ontario, Gelderland, Britain. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07265596's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI